ALEXANDER GORDON DOYLE
Prescription History 1275977365
Psychiatry & Neurology - Epilepsy in Dallas, TX


Quality Rating: 74.59 out of 100 score

NPI Status: Active since April 19, 2013

Contact Information

5323 HARRY HINES BLVD
GRADUATE MEDICAL EDUCATION
DALLAS, TX
ZIP 75390
Phone: (214) 590-8058

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ALEXANDER GORDON DOYLE, an active Epilepsy specialist practicing in Dallas, TX. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 547 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 112 claims alone.


Aptiom

Generic Formulation: Eslicarbazepine AcetateSpecialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 28.0
Days Supply 840
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply887
Conservative Utilization

This provider writes prescriptions for this formulation 46.7% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,130.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,070.63

State Avg Cost Per Claim

$1,443.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

Banzel

Generic Formulation: RufinamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills15.8
Peer Average Days Supply468
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $85,993.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,166.12

State Avg Cost Per Claim

$4,708.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.

Briviact

Generic Formulation: BrivaracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 53
30-Day Fills 81.0
Days Supply 2,430
TX State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills37.1
Peer Average Days Supply1,057
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 55.9% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $124,470.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,348.50

State Avg Cost Per Claim

$1,605.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brivaracetam is used to treat seizures (epilepsy).

Carbamazepine Er

Generic Formulation: CarbamazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 23.0
Days Supply 669
TX State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills33.6
Peer Average Days Supply965
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,787.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$214.39

State Avg Cost Per Claim

$158.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.

Therapeutic Applications

Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

Clobazam

Generic Formulation: ClobazamSpecialty: Neurology
Provider Metrics Summary
Total Claims 43
30-Day Fills 54.2
Days Supply 1,626
TX State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills46.3
Peer Average Days Supply1,317
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,745.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$110.36

State Avg Cost Per Claim

$284.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Clonazepam

Generic Formulation: ClonazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.3
Days Supply 606
TX State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills56.7
Peer Average Days Supply1,631
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.0% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $796.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.91

State Avg Cost Per Claim

$9.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Epidiolex

Generic Formulation: Cannabidiol (Cbd)Specialty: Neurology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,077
TX State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply1,049
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $189,699.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,626.82

State Avg Cost Per Claim

$4,570.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound isolated from Cannabis sativa extract.

Therapeutic Applications

This medication is used to treat seizures due to certain medical conditions (such as Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex - TSC). It is not known how this medication works for these seizures. Cannabidiol belongs to a class of drugs known as cannabinoids.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 80
30-Day Fills 133.1
Days Supply 3,961
TX State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills41.3
Peer Average Days Supply1,146
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 142.4% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,155.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$276.95

State Avg Cost Per Claim

$313.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 66
30-Day Fills 137.8
Days Supply 3,979
TX State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills66.3
Peer Average Days Supply1,949
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,089.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.66

State Avg Cost Per Claim

$17.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 112
30-Day Fills 257.7
Days Supply 7,689
TX State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills80.3
Peer Average Days Supply2,310
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 124.0% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,060.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.11

State Avg Cost Per Claim

$43.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Oxcarbazepine

Generic Formulation: OxcarbazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 34.0
Days Supply 1,020
TX State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills49.3
Peer Average Days Supply1,425
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.1% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,169.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$83.56

State Avg Cost Per Claim

$64.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Pregabalin

Generic Formulation: PregabalinSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 540
TX State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,896
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.8% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $230.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.46

State Avg Cost Per Claim

$43.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Rufinamide

Generic Formulation: RufinamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply537
Conservative Utilization

This provider writes prescriptions for this formulation 36.8% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,513.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,459.42

State Avg Cost Per Claim

$1,732.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.

Topiramate

Generic Formulation: TopiramateSpecialty: Neurology
Provider Metrics Summary
Total Claims 26
30-Day Fills 50.6
Days Supply 1,518
TX State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills59.1
Peer Average Days Supply1,748
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $343.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.21

State Avg Cost Per Claim

$18.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.

Therapeutic Applications

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache, treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room). Topiramate is known as an anticonvulsant or antiepileptic drug.

Vimpat

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills39.6
Peer Average Days Supply1,051
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.6% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,079.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,173.27

State Avg Cost Per Claim

$1,195.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Xcopri

Generic Formulation: CenobamateSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
TX State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills32.8
Peer Average Days Supply954
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,249.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,303.52

State Avg Cost Per Claim

$1,239.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of seizure disorder (partial onset). It is not known exactly how it works, but it may affect the action of some nerves that cause seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ALEXANDER GORDON DOYLE provides transparency into local medical care patterns within Dallas, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Epilepsy ** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.